688136 Stock Overview
Engages in the research and development, production, and sale of recombinant protein drugs and microbial preparations in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Kexing Biopharm Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥19.72 |
| 52 Week High | CN¥22.82 |
| 52 Week Low | CN¥10.61 |
| Beta | 0.84 |
| 1 Month Change | 19.08% |
| 3 Month Change | 34.79% |
| 1 Year Change | -0.40% |
| 3 Year Change | -29.29% |
| 5 Year Change | n/a |
| Change since IPO | -51.91% |
Recent News & Updates
Recent updates
There's No Escaping Kexing Biopharm Co., Ltd.'s (SHSE:688136) Muted Revenues Despite A 36% Share Price Rise
Oct 08
Kexing Biopharm Co., Ltd.'s (SHSE:688136) Share Price Boosted 36% But Its Business Prospects Need A Lift Too
May 21Shandong Kexing Bioproducts Co,.Ltd (SHSE:688136) Held Back By Insufficient Growth Even After Shares Climb 25%
Mar 08Shareholder Returns
| 688136 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 12.3% | -3.0% | -2.1% |
| 1Y | -0.4% | -19.0% | 9.8% |
Return vs Industry: 688136 exceeded the CN Biotechs industry which returned -19% over the past year.
Return vs Market: 688136 underperformed the CN Market which returned 9.8% over the past year.
Price Volatility
| 688136 volatility | |
|---|---|
| 688136 Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 688136 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688136's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 1,014 | Yanqing Zhao | www.kexing.com |
Kexing Biopharm Co., Ltd. engages in the research and development, production, and sale of recombinant protein drugs and microbial preparations in China and internationally. The company focuses on pharmaceutical research in the therapeutic fields of antiviral, tumor and immunity, blood, digestion, and degenerative diseases. Its products include recombinant human interferon a1b, human erythropoietin, and human granulocyte stimulating factor; Clostridium butyricum combined live bacteria powder; Kehuang Capsule, a Chinese patent medicine; Entecavir, a chemical drug; and liraglutide, a human glucagon-like peptide-1, as well as Albumin-Paclitaxel, Infliximab, Bevacizumab, adalimumab, trastuzumab, neratinib maleate tablets, and lenalidomide capsules.
Kexing Biopharm Co., Ltd. Fundamentals Summary
| 688136 fundamental statistics | |
|---|---|
| Market cap | CN¥3.89b |
| Earnings (TTM) | -CN¥118.80m |
| Revenue (TTM) | CN¥1.33b |
2.9x
P/S Ratio-32.8x
P/E RatioIs 688136 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688136 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.33b |
| Cost of Revenue | CN¥407.21m |
| Gross Profit | CN¥921.08m |
| Other Expenses | CN¥1.04b |
| Earnings | -CN¥118.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | 69.34% |
| Net Profit Margin | -8.94% |
| Debt/Equity Ratio | 69.9% |
How did 688136 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 18:16 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kexing Biopharm Co., Ltd. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kai Wang | Citic Securities Co., Ltd. |
| Yin Ye | Ping An Securities Co. Ltd. |
| Song Yang | Tianfeng Securities Brokerage Co., Ltd |